Brief: AN2 Therapeutics Announces Plans To Advance Oral Epetraborole Into Phase 2 Study For Polycythemia Vera (PV)
03/03/2026 21:06
March 3 (Reuters) - AN2 Therapeutics Inc ANTX.O: AN2 THERAPEUTICS ANNOUNCES PLANS TO ADVANCE ORAL EPETRABOROLE INTO PHASE 2 STUDY FOR POLYCYTHEMIA VERA (PV) AN2 THERAPEUTICS INC - PHASE 2 STUDY EXPECTED TO BEGIN IN Q3 2026 WITH DATA READOUTS AS EARLY AS Q4 2026 AND THROUGHOUT 2027 Source text: ID:nBwBt1bga Further company coverage: ANTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AN2 Therapeutics
See all newsBrief: AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(C)(4)
Brief: An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk
AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
AN2 Therapeutics Q2 net loss widens on higher R&D costs
AN2 Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview